Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

Go back to Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021
(NASDAQ: KYMR) Delayed: 50.55 -1.4 (2.69%)
Previous Close $51.95    52 Week High
Open $51.94    52 Week Low
Day High $52.37    P/E N/A 
Day Low $48.93    EPS
Volume 319,910